Health

Gilead’s remdesivir slows disease progression in monkeys with COVID-19

Written by corres2

[ad_1]

FILE PHOTO: Two ampules of Ebola drug Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo

(Reuters) – Gilead Sciences Inc’s antiviral drug, remdesivir, prevented lung disease in macaques infected with the new coronavirus, according to a study published in medical journal Nature on Tuesday.

Remdesivir has been cleared for emergency use in severely-ill patients in the United States, India and South Korea. Some European nations are also using it under compassionate programs.

Trials of the drug in humans are ongoing, and early data has shown the drug helped patients recover more quickly from the illness caused by the new coronavirus.

In the study, 12 monkeys were deliberately infected with the coronavirus, and half of them were given early treatment with remdesivir.

Macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors. go.nature.com/2Yj9xq2

Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty

[ad_2]
Source link

About the author

corres2

Leave a Comment

x

COVID-19

India
Confirmed: 9,351,109Deaths: 136,200
x

COVID-19

World
Confirmed: 61,636,609Deaths: 1,442,572